Bruker Corporation
BRKRHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Bruker Corporation (BRKR) is listed under Medical Devices. The company carries a $8.77B market cap, placing it firmly in the mid-cap category. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Market Cap
$8.77B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
23.97
EPS (TTM)
$-0.70
EPS (Fwd)
$2.40
ROE
-3.0%
ROA
3.1%
Cash
$184.9M
Total Debt
$1.86B
Free CF
$179.9M
52W Change
49.0%
Annual Financials
Cash vs Debt
Where BRKR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BRKR finished 6.48% above its 150-day moving average ($52.00) and 11.14% above its 200-day moving average ($49.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BRKR overbought or oversold?
At the October 20, 2026 close, BRKR's RSI(14) was 25.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BRKR has $184.9M in cash with $1.86B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $179.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -3.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.53B (2022) to $3.44B (2025), reflecting a 36% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing BRKR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.